Historic Reclassification: US Moves Medical Marijuana to Schedule III, Paving Way for Research and Tax Relief
In a landmark decision, the United States Department of Justice has reclassified state-licensed medical marijuana to Schedule III of the Controlled Substances Act. The move, signed by Acting Attorney General Todd Blanche on April 23, 2026, at the behest of President Donald Trump, signifies a monumental shift in federal drug policy, though it does not legalize cannabis at the federal level for recreational use.
This reclassification, which had been in the works since a 2022 Biden administration directive and an executive order from President Trump in December 2025, formally acknowledges the accepted medical use of marijuana and its lower potential for abuse compared to Schedule I substances. Previously, marijuana shared its Schedule I classification with drugs like heroin and LSD, substances deemed to have no accepted medical use and a high potential for dependence.
The implications of this change are far-reaching. For the 40 states with legal medical marijuana programs, licensed producers will now be eligible for significant tax benefits, as they can deduct ordinary business expenses previously disallowed under federal tax code Section 280E. Furthermore, the rescheduling is expected to accelerate medical research by reducing regulatory barriers, making it easier for scientists to study cannabis-derived substances and conduct clinical trials evaluating their safety and efficacy.
While this is a pivotal step, several key aspects remain to be addressed. The reclassification specifically applies to state-licensed medical marijuana and FDA-approved cannabis products; it does not impact the federal status of marijuana for recreational use. Additionally, significant questions persist regarding how financial institutions and other third parties will adapt to this new classification, especially in the absence of federal banking legislation like the SAFE Banking Act.
The Drug Enforcement Administration (DEA) is set to hold an expedited administrative hearing on June 29, 2026, to further consider the broader rescheduling of marijuana. This process is anticipated to bring more clarity to the federal government's regulation of cannabis products under a Schedule III framework.
The move to Schedule III aligns federal policy more closely with the growing number of states legalizing cannabis for medical purposes and signals a broader trend toward reassessing previously restricted psychoactive compounds with emerging clinical evidence, drawing parallels to the increasing federal interest in psychedelic research.
This historic reclassification represents one of the most significant federal cannabis policy shifts in decades, opening new avenues for research, patient access, and economic opportunities within the medical marijuana sector, even as regulatory and legislative challenges continue to unfold.
This reclassification, which had been in the works since a 2022 Biden administration directive and an executive order from President Trump in December 2025, formally acknowledges the accepted medical use of marijuana and its lower potential for abuse compared to Schedule I substances. Previously, marijuana shared its Schedule I classification with drugs like heroin and LSD, substances deemed to have no accepted medical use and a high potential for dependence.
The implications of this change are far-reaching. For the 40 states with legal medical marijuana programs, licensed producers will now be eligible for significant tax benefits, as they can deduct ordinary business expenses previously disallowed under federal tax code Section 280E. Furthermore, the rescheduling is expected to accelerate medical research by reducing regulatory barriers, making it easier for scientists to study cannabis-derived substances and conduct clinical trials evaluating their safety and efficacy.
While this is a pivotal step, several key aspects remain to be addressed. The reclassification specifically applies to state-licensed medical marijuana and FDA-approved cannabis products; it does not impact the federal status of marijuana for recreational use. Additionally, significant questions persist regarding how financial institutions and other third parties will adapt to this new classification, especially in the absence of federal banking legislation like the SAFE Banking Act.
The Drug Enforcement Administration (DEA) is set to hold an expedited administrative hearing on June 29, 2026, to further consider the broader rescheduling of marijuana. This process is anticipated to bring more clarity to the federal government's regulation of cannabis products under a Schedule III framework.
The move to Schedule III aligns federal policy more closely with the growing number of states legalizing cannabis for medical purposes and signals a broader trend toward reassessing previously restricted psychoactive compounds with emerging clinical evidence, drawing parallels to the increasing federal interest in psychedelic research.
This historic reclassification represents one of the most significant federal cannabis policy shifts in decades, opening new avenues for research, patient access, and economic opportunities within the medical marijuana sector, even as regulatory and legislative challenges continue to unfold.
This article and image are AI generated. For informational purposes only.